Biogen (BIIB) PT Lowered to $355 at Leerink Partners on Reduced Aducanumab Probability of Success
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Sola News Negative for Biogen (BIIB) as Latest in Numerous Failures for the Mechanism - Baird
November 23, 2016 10:40 AM ESTBaird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB), saying Eli Lilly's Solanezumab failure is a negative for the company.,
Skorney commented, "Lilly's registrational EXPEDITION 3 trial for solanezumab in mild Alzheimer's patients failed. Though some secondary endpoints favored sola, Lilly's admission that... More
Mizuho Sees Near-Term Trading Opportunity in Biogen (BIIB) Amid Weakness
November 23, 2016 9:48 AM ESTMizuho analyst Salim Syed weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly announced this morning that its Alzheimer's drug, Solanezumab Phase 3 study has failed and it will not pursue approval which has implications to Biogen's Aducanumab.
Syed commented, "While we are... More
Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital
November 23, 2016 9:27 AM ESTBMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) with shares down on Eli Lilly's solanezumab's failure. The analyst said the news decreases the value of aducanumab's.
Somaiya commented, "We expect BIIB shares to trade down on solanezumab's failure, as we... More
Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)
November 23, 2016 9:24 AM ESTToday's Pre-Open Stock Movers
Medigus Ltd. (NASDAQ: MDGS) 41.6% HIGHER; announced a distribution agreement in Italy with INNOVAMEDICA S.p.A, a privately owned distributor of minimally invasive medical devices. Under terms of the four-year agreement which will take effect January 1st 2017, INNOVAMEDICA S.p.A. will be required to purchase at least 1M of Medigus Ultrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement.
Euroseas Ltd. (Nasdaq:... More
Sola Failures Appears 'Near-Perfect' for Biogen (BIIB) - Stifel
November 23, 2016 8:40 AM ESTStifel analyst Thomas Shrader weighed in on Biogen (NASDAQ: BIIB) Eli Lilly's Solanezumab did not meet its primary endpoint in the EXPEDITION3 clinical trial. Solanezumab's near-miss is near-Perfect for Biogen, Shrader said.
Shrader commented, "Solanezumab did not meet its primary endpoint in... More
Forward Pharma (FWP): Reiterating Buy Ahead Of Next Week's Litigation - Leerink
November 23, 2016 8:36 AM ESTLeerink Partners analyst, Jason Gerberry, reiterated his Outperform rating on shares of Forward Pharma (NASDAQ: FWP) ahead of the interference oral arguments. The analyst is modeling 65% odds to FWP prevailing in its patent interference dispute with Biogen (NASDAQ:... More
Eli Lilly Sola Failure is a 'Serious Blow' to Biogen (BIIB) and Others in AD Field - Leerink
November 23, 2016 7:57 AM ESTLeerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly (NYSE: LLY) announced that the solanezumab (sola) phase III trial in patients with mild Alzheimers disease failed to meet statistical significance on the primary endpoint and only... More
Dow, S&P 500 set record high closes ahead of holiday
November 23, 2016 7:33 AM ESTBy Caroline Valetkevitch
NEW YORK (Reuters) - The Dow and the S&P 500 eked out record high closes on Wednesday ahead of the Thanksgiving holiday, helped by gains in industrial stocks, though losses in technology shares limited the advance and weighed on the Nasdaq.
Caterpillar (NYSE: CAT) rose 2.7 percent and hit the highest in about two years, while Deere (NYSE: DE) jumped 11 percent to a record high close after the farm equipment maker reported a much smaller-than-expected decline in profit.
Industrial... More
Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's
November 23, 2016 7:05 AM ESTBiogen (NASDAQ: BIIB) is recently down 3% in the premarket following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's. November weekly call option implied volatility is at 30, December is at 48; compared to its 52-week range of 28 to 45.
... MoreBiogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab Failure
November 23, 2016 6:52 AM ESTBiogen (NASDAQ: BIIB) is trading down 1% in pre-open trade following news Eli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... More